Skip to Content
Merck
All Photos(1)

Key Documents

B1680

Sigma-Aldrich

Bradyzide di(trifluoroacetate) salt hydrate

≥98%

Synonym(s):

(S)-1-[4-(4-Benzhydrylthiosemicarbazido)-3-nitrobenzenesulfonyl]-pyrrolidine-2-carboxylic acid [2-[(2-dimethylaminoethyl)methylamino]ethyl] amide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C32H42N8O5S2 · 2C2HF3O2 · xH2O
Molecular Weight:
910.90 (anhydrous basis)
MDL number:
UNSPSC Code:
41106200
NACRES:
NA.32

Assay

≥98%

form

solid

solubility

H2O: >40 mg/mL

storage temp.

−20°C

Biochem/physiol Actions

Potent, orally active, non-peptide B2 bradykinin receptor antagonist.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

G M Burgess et al.
British journal of pharmacology, 129(1), 77-86 (2000-02-29)
Bradyzide is from a novel class of rodent-selective non-peptide B(2) bradykinin antagonists (1-(2-Nitrophenyl)thiosemicarbazides). Bradyzide has high affinity for the rodent B(2) receptor, displacing [(3)H]-bradykinin binding in NG108-15 cells and in Cos-7 cells expressing the rat receptor with K(I) values of
Marielza Andrade Nunes et al.
Pharmaceuticals (Basel, Switzerland), 13(10) (2020-10-07)
Alzheimer's disease is mainly characterized by remarkable neurodegeneration in brain areas related to memory formation. This progressive neurodegeneration causes cognitive impairment, changes in behavior, functional disability, and even death. Our group has demonstrated changes in the kallikrein-kinin system (KKS) in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service